Klebsiella pneumoniae carbapenemase variants: the new threat to global public health.

ABSTRACT: SUMMARYKlebsiella pneumoniae carbapenemase (KPC) variants, which refer to the substitution, insertion, or deletion of amino acid sequence compared to wild bla_KPC type, have reduced utility of ceftazidime-avibactam (CZA), a pioneer antimicrobial agent in treating carbapenem-resistant Enterobacterales infections. So far, more than 150 bla_KPC variants have been reported worldwide, and most of the new variants were discovered in the past 3 years, which calls for public alarm. The KPC variant protein enhances the affinity to ceftazidime and weakens the affinity to avibactam by changing the KPC structure, thereby mediating bacterial resistance to CZA. At present, there are still no guidelines or expert consensus to make recommendations for the di

SUBMITTER: Ding L 

PROVIDER: S-EPMC10732083 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature